Iron-doped nanozymes with spontaneous peroxidase-mimic activity as a promising antibacterial therapy for bacterial keratitis 

Xiwen Geng et al.

Smart Med. 2024 May 22;3(2):e20240004. doi: 10.1002/SMMD.20240004. eCollection 2024 Jun.

Published on August 27, 2024

Abstract

ABSTRACT

The development of non-antibiotic pharmaceuticals with biocompatible and efficient antibacterial properties is of great significance for the treatment of bacterial keratitis. In this study, we have developed antibacterial iron-doped nanozymes (Fe3+-doped nanozymes, FNEs) with distinguished capacity to fight against bacterial infections. The iron-doped nanozymes are composed of Fe3+ doped zeolitic imidazolate framework-8 (Fe/ZIF-8) and polyethylene imide (PEI), which were functionally coated on the surface of Fe/ZIF-8 and imparted the FNEs with improved water dispersibility and biocompatibility. FNEs possess a significant spontaneous peroxidase-mimic activity without the need for external stimulation, thus elevating cellular reactive oxygen species level by catalyzing local H2O2 at the infection site and resulting in bacteria damaged to death. FNEs eliminated 100% of Staphylococcus aureus within 6 h, and significantly relieved inflammation and bacterial infection levels in mice bacterial keratitis, exhibiting higher bioavailability and a superior therapeutic effect compared to conventional antibiotic eye drops. In addition, the FNEs would not generate drug resistance, suggesting that FNEs have great potential in overcoming infectious diseases caused by antimicrobial resistant bacteria.

PMID:39188699 | PMC:PMC11236036 | DOI:10.1002/SMMD.20240004

 Read More

← Back to Publications
Sam van Puyenbroeck et al.Nat Methods. 2026 Nov 3. doi: 10.1038/s41592-026-03301-9. Online ahead of print.
Xiaofei Chen et al.J Orthop Translat. 2026 Oct 25;61:101241. doi: 10.1016/j.jot.2026.101241. eCollection 2026 Nov.
Saeka Shimochi et al.Pharmaceuticals (Basel). 2026 Oct 10;19(10):1610. doi: 10.3390/ph19101610.
Kim Kreuze et al.Res Sq [Preprint]. 2026 Oct 5:rs.3.rs-11232673. doi: 10.21203/rs.3.rs-11232673/v1.
Prince Dadson et al.Int J Obes (Lond). 2026 Oct 16. doi: 10.1038/s41366-026-02243-8. Online ahead of print.